BIOLOGICS LICENSE APPLICATION OF RISVUTATUG REZETCAN (HS-20093) FOR INJECTION FOR SMALL CELL LUNG CANCER ACCEPTED BY THE NMPA
SHANGHAI, September 7, 2026 — Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma", 3692.HK) today announced that the biologics license applic...
2026.09.07